Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006888 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
A Phase 3 study, sponsored by ICON Bioscience.
- Completed
- Registry status
- Phase 3
- Development phase
- 394
- Enrollment target
NCT02006888: Completed Phase 3 study, sponsored by ICON Bioscience.
NCT02006888 is a Phase 3 study that has completed, run by ICON Bioscience. The registered enrollment target is 394 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02006888, a Phase 3 study, has completed, sponsored by ICON Bioscience.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 394 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.
Primary Outcome
The primary efficacy outcome is anterior chamber cell clearing in the study eye at Day 8. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are
Interventions
- DRUG Placebo
- DRUG IBI-10090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
What the finished NCT02006888 record still lists
NCT02006888 is an interventional study that assigns participants to a tested intervention. The registered 394 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02006888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02006888 about?
NCT02006888 is a clinical study titled "The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery". The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.
What is the current status of trial NCT02006888?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2014-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02006888?
The interventions under investigation include: Placebo (DRUG), IBI-10090 (DRUG).
Who is sponsoring clinical trial NCT02006888?
This trial is sponsored by ICON Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02006888's enrollment target sits among peer trials
394 967th of 2000 higher than 1,034 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia